Molecular therapy for Myocardial Infarction: Sirtuin-7 improves myocardial function after myocardial infarction via up-regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 15/October/2016, 11.58 am

Life-extension therapy: MiR-451 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via upregulation of its target genes, 15/October/2016, 9.03 am
October 15, 2016
Natural product anti-inflammatory therapy for upper respiratory tract inflammatory diseases: Ursolic acid, found in apples, increases the expression of negative regulator of inflammation MyD88(s), inhibits pro-inflammatory mediators in lungs, and alleviates the common respiratory pathogen nontypeable Haemophilus influenzae (NTHi)-exacerbated asthma & chronic obstructive pulmonary disease via up-regulation of its target gene, 15/October/2015, 12.22 pm
October 15, 2016
Show all

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction: Sirtuin-7 improves myocardial function after myocardial infarction via  up-regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10)


Significance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.

This study suggests a small molecule-based cardiac regeneration therapy. HMGI-C, by decreasing the expression of its target gene, it may increase the expression of PNUTS/PPP1R10. Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardiomyocyte survival/regeneration.

Thus, by treating myocardial patients with Sirtuin-7 activators, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing Sirtuin-7 activators” may be used to improve cardiac function after myocardial infarction


Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Molecular therapy for Myocardial Infarction: Sirtuin-7  improves myocardial function after myocardial infarction via  up-regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 15/October/2016, 11.58 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation


Amount: $200#

Undisclosed information: How Sirtuin-7 increases the expression of PNUTS/PPP1R10

satisfaction-guaranted-if-not-refunded

Results guaranteed if not refunded

Comments are closed.